Middle East Pharmaceutical Industries Company (TADAWUL:4016)

Market Cap	1.94B -28.2%
Revenue (ttm)	460.48M +16.9%
Net Income	97.01M +21.5%
EPS	4.85 +21.5%
Shares Out	20.00M
PE Ratio	20.04
Forward PE	16.31
Dividend	2.50 (2.57%)
Ex-Dividend Date	Mar 30, 2026

Volume	137,266
Average Volume	54,358
Open	97.70
Previous Close	97.80
Day's Range	96.50 - 97.80
52-Week Range	94.30 - 139.00
Beta	0.63
RSI	32.45
Earnings Date	Mar 26, 2026

About TADAWUL:4016

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. Its product portfolio includes dermatological, respiratory, cardiovascular, alimentary and anti-infectives, musculoskeletal, genitourinary systems, and CNS. The company also exports its products. Middle East Pharmaceutical Industries Company was formerly known...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 632
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2025, TADAWUL:4016's revenue was 460.48 million, an increase of 16.87% compared to the previous year's 394.00 million. Earnings were 97.01 million, an increase of 21.49%.